News

Chemestmed and Tehistark have secured €150,000 funding from the Estonian Business and Innovation Agency to develop and test an AI-powered platform for preparing Investigational New Drug (IND) documentation. The collaboration aims to transform the regulatory submission process using experimental data from Chemestmed’s preclinical programs.

Tehistark’s AI-driven platform (AutoDossier) streamlines and automates the traditionally manual process of regulatory authoring, significantly reducing time and costs while ensuring compliance and audit readiness. Through this partnership, Chemestmed will provide GLP data across multiple formats to test the platform and deliver critical user feedback. The project will focus on advancing Tehistark’s current platform. Key goals include developing a real-world IND draft and quantifying time savings by comparing manual versus AI-supported document preparation.

For Chemestmed, the project provides a regulatory roadmap by delivering a gap-analyzed, expert-reviewed IND draft, helping the company plan proactively and accelerate future submissions. This close collaboration between regulatory and AI experts marks a significant step forward in integrating cutting-edge technology into life sciences, supporting faster, smarter, and more efficient drug development.